FDA OKs First-Line Pembro With Chemo for Gastric/GEJ Cancer FDA OKs First-Line Pembro With Chemo for Gastric/GEJ Cancer
Adding pembrolizumab to chemotherapy had significant benefits in patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Hematology | HER2